)
Immunology
Driven by Our Patients
Congress Materials
- ESID 2022 | 12–15 October 2022 | View Materials
- ESID 2020 | 14–17 October 2020 | View Materials
Immunology Resources
HAE Interactive Patient Case Study Tool: Test your knowledge and understanding of managing patients with HAE
Patient Case Study Infographics: Learn more about real- world experience of subcutaneous Berinert® 2000/3000 (C1-INH)
Prescribing information for HAEGARDA® and Berinert® may vary depending on local approval in each country. Therefore, before prescribing HAEGARDA® or Berinert®, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics (SmPC) in your country.
HAEGARDA® and Berinert® are not available in all countries. Consult the CSL Behring Global Products List to see if HAEGARDA® and Berinert® are available in your country.
- HAEGARDA US Prescribing Information
- HAEGARDA Full US Important Safety Information
- Berinert US Prescribing Information
- Berinert Full US Important Safety Information
- Berinert 500/1500 Summary of Product Characteristics
- Berinert 2000/3000 Summary of Product Characteristics
References
- CSL Ltd Annual Report 2022. CSL Ltd. Published 2022. Accessed September 6, 2022. https://investors.csl.com/annualreport/2022/2/
CMD-BRN-0052
August 2021